CA-ARIBIO-CO.,-LTD.
31.3.2023 18:01:37 CEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip is Set to Launch AgentOS to Orchestrate Autonomous AI-Driven Customer Journeys at Scale26.2.2026 10:00:00 CET | Press release
New platform reinforces Infobip’s shift to AI-first customer experience in its 20th year Global AI-first cloud communications platform Infobip, which celebrates its 20th anniversary this year, is set to launch its AI-native fully managed solution AgentOS. The new platform builds on Infobip's recently launched AI Agents, the intelligent foundation for autonomous customer communications. AgentOS is a major step in Infobip’s evolution from communications platform to intelligent orchestration layer for the AI era, enabling businesses to move from campaigns and workflows to autonomous, goal-driven interactions. AI communication models enable autonomous customer communications, hyper-personalization and highly engaging content across multiple channels. However, AI agents need a unified view of all customer touchpoints to deliver such benefits. Businesses must eliminate data silos. Yet readiness is low. Few enterprise AI agent projects reach production due to unstructured data and internal ba
Vonage Brings Network Innovation to Mobile World Congress 202626.2.2026 09:33:00 CET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), is set to make an impact at Mobile World Congress (MWC) 2026, the connectivity industry’s most influential exhibition, taking place March 2–5 in Barcelona. Vonage’s presence will include product demos, thought leadership sessions, and ecosystem collaborations, showcasing how the Company is leading the transformation of mobile networks into the enterprise platform of the future. “The digital arena is undergoing a fundamental shift as mobile networks transform into platforms and redefine the enterprise technology stack,” said Neelam Sandhu, Chief Marketing Officer at Vonage. “Mobile World Congress is where possibilities turn into real-world applications, and we demonstrate the capabilities and intelligence embedded in mobile networks to developers and enterprises, showcasing how they are becoming engines of innovation for industries worldwide. I am excited for Vonage to be at the helm of the thought leadership conversation and to reveal our latest
KAYTUS Enhances KSManage with Full-Stack O&M Visibility for AI Data Centers26.2.2026 09:02:00 CET | Press release
KSManage is designed for next-gen AI data center, with four-level visibility across components, servers and cabinets, clusters, and AI jobs, and ensures the AI data centers’ high availability As AI data centers scale to support increasingly complex AI workloads, traditional IT monitoring can no longer provide the visibility required for reliable operations. KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, has significantly upgraded KSManage, introducing full-stack, four-level visibility across components, servers and cabinets, clusters, and AI jobs, to address the challenges of complex troubleshooting, higher component failure rates, intricate application dependencies and delayed responses to operations and maintenance (O&M) incidents generated by demanding AI data center operations. The enhanced platform enables precise fault localization, faster incident response, and proactive operations. With KSManage, KAYTUS helps customers maximize availability, improve o
NIPPON KINZOKU to Expand Sales of Ultra-Light Magnesium Alloy Foil: Empowering the Future with Eco-Product26.2.2026 09:01:00 CET | Press release
Driving Innovation in XR and Transportation with Unmatched Lightness and Damping Performance NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) is proud to announce a strategic expansion in the sales of its Magnesium Alloy Foil. Positioned as a core "Eco-Product" that contributes to reducing environmental impact, this high-performance material addresses diverse industrial needs by offering the lightest weight among practical metals combined with exceptional vibration-damping properties. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226621455/en/ Magnesium Alloy Foil (Alloy: AZ31B, Thickness: 0.05 mm, Width: 100 mm) Magnesium alloy is gaining global attention for its incredibly low specific gravity approximately 1/4.5 that of steel and 1/2.5 that of titanium—while maintaining excellent specific strength, stiffness, and damping performance. Target Markets: Beyond mobile PCs and high-end smartphones, we
Mobileum Enables GSMA Industry Services’ Launch of VOLTIS 5G Extension, Streamlining Global 5G Roaming Verification26.2.2026 09:00:00 CET | Press release
New framework reduces bilateral testing complexity and accelerates time-to-market for next-generation roaming services Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, today announced its expanded role in enabling GSMA Industry Services’ launch of the VOLTIS (Voice over LTE Interoperability & Testing Service) 5G Extension Verification Program. The new extended program goes beyond the existing VoLTE/IMS verification framework to include 5G readiness verification, providing operators with a standardized path to validate next-generation roaming and interoperability. As an appointed verification partner, Mobileum manages the end-to-end validation process, from test planning and resource validation through test execution, troubleshooting, and final reporting, delivering a streamlined, globally recognized verification experience for operators worldwide. As 5G roaming scales globally, operators face increased complexity in validating VoLTE and 5G inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom